Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | Pomoč | SLO | ENG

Naslov:Consequence of the introduction of routine FCH PET/CT imaging for patients with prostate cancer : a dual centre survey
Avtorji:ID Hodolič, Marina (Avtor)
ID Michaud, Laure (Avtor)
ID Huchet, V. (Avtor)
ID Balogova, S. (Avtor)
ID Nataf, V. (Avtor)
ID Kerrou, K. (Avtor)
ID Vereb, M. (Avtor)
ID Fettich, Jurij (Avtor)
ID Talbot, Jean-Noël (Avtor)
Datoteke:URL URL - Izvorni URL, za dostop obiščite http://www.degruyter.com/view/j/raon.ahead-of-print/raon-2013-0049/raon-2013-0049.xml
 
.pdf PDF - Predstavitvena datoteka, prenos (595,04 KB)
MD5: B7D5FAFB079E28862E97A704F10FC7DC
 
Jezik:Angleški jezik
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:Logo OI - Onkološki inštitut Ljubljana
Povzetek:Background. Fluorocholine(18F) (FCH) was introduced at the beginning of April 2010 in France, Slovenia and three other EU member states for the localisation of bone metastases of prostate cancer with PET. The aim of the study was to compare the evolution of diagnostic imaging in patients with prostate cancer using a new radiopharmaceutical FCH, observed in France and in Slovenia, and to quantify the consequence of the results of new imaging modality on the detection rate of abnormal metastases and recurrences of prostate cancer.Patients and methods. In two centres (France/Slovenia), a survey of the number of nuclear medicine examinations in patients with prostate cancer was performed, covering 5 quarters of the year since the introduction of FCH. For each examination, the clinical and biological circumstances were recorded, as well as the detection of bone or soft tissue foci.Results. Six hundred and eighty-eight nuclear medicine examinations were performed impatients with prostate cancer. Nuclear medicine examinations were performed for therapy monitoring and follow-up in 23% of cases. The number of FCH PET/CT grew rapidly between the 1st and 5th period of the observation (+220%), while the number of bone scintigraphies (BS) and fluoride(18F) PET/CTs decreased (-42% and -23% respectively). Fluorodeoxyglucose(18F) (FDG) PET/CT remained limited to few cases of castrate-resistant or metastatic prostate cancer in Paris. The proportion of negative results was significantly lower with FCH PET/CT (14%) than with BS (49%) or fluoride(18F) PET/CT (54%). For bone metastases, the detection rate was similar, but FCH PET/CT was performed on average at lower prostate-specific antigen (PSA) levels and was less frequently doubtful (4% vs. 28% for BS). FCH PET/CT also showed foci in prostatic bed (53% of cases) or in soft tissue (35% of cases).Conclusions. A rapid development of FCH PET/CT was observed in both centres and led to a higher detection rate of prostate cancer lesions.
Ključne besede:prostate cancer, PET/CT, fluorocholine (FCH), fluoride(18F), bone scintigraphy, indication of imaging, prostata, rak (medicina), slikovna diagnostika
Status publikacije:Objavljeno
Verzija publikacije:Objavljena publikacija
Datum objave:01.03.2014
Založnik:Association of Radiology and Oncology
Leto izida:2014
Št. strani:str. 20-28
Številčenje:Vol. 48, no. 1
Izvor:Ljubljana
PID:20.500.12556/DiRROS-18614 Novo okno
UDK:616.65-006-07
ISSN pri članku:1318-2099
DOI:10.2478/raon-2013-0049 Novo okno
COBISS.SI-ID:1067180 Novo okno
Avtorske pravice:by Authors
Datum objave v DiRROS:04.04.2024
Število ogledov:1053
Število prenosov:737
Metapodatki:XML DC-XML DC-RDF
:
HODOLIČ, Marina, MICHAUD, Laure, HUCHET, V., BALOGOVA, S., NATAF, V., KERROU, K., VEREB, M., FETTICH, Jurij in TALBOT, Jean-Noël, 2014, Consequence of the introduction of routine FCH PET/CT imaging for patients with prostate cancer : a dual centre survey. Radiology and oncology [na spletu]. 2014. Vol. 48, no. 1, p. 20–28. [Dostopano 28 april 2025]. DOI 10.2478/raon-2013-0049. Pridobljeno s: https://dirros.openscience.si/IzpisGradiva.php?lang=slv&id=18614
Kopiraj citat
  
Objavi na:Bookmark and Share


Iščem podobna dela...Prosim, počakajte...
Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.

Gradivo je del revije

Naslov:Radiology and oncology
Skrajšan naslov:Radiol. oncol.
Založnik:Slovenian Medical Society - Section of Radiology, Croatian Medical Association - Croatian Society of Radiology
ISSN:1318-2099
COBISS.SI-ID:32649472 Novo okno

Nazaj